GF for visual blindness in patient affected by glioma - ND
- Conditions
- gloma with visual blindnessMedDRA version: 9.1Level: LLTClassification code 10030935Term: Optic nerve glioma
- Registration Number
- EUCTR2008-001438-29-IT
- Lead Sponsor
- POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
children between 7-13 years old affected by glioma
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
na
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of GF therapy address optic nerve glioma-induced visual blindness in MedDRA 10030935 patients?
How does GF treatment compare to standard-of-care for visual loss in optic nerve glioma (MedDRA 10030935) cases?
Which biomarkers correlate with GF efficacy in optic nerve glioma patients with visual impairment?
What are the safety profiles and adverse event management strategies for GF in optic nerve glioma trials?
Are there combination therapies or alternative compounds targeting optic nerve glioma (MedDRA 10030935) similar to GF?